Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Atrial Fibrillation Devices are the devices used for atrial fibrillation therapy, including access, diagnostic, visualization and ablation products to assist physicians in diagnosing and treating various irregular heart rhythms.
In the last several years, global market of Atrial Fibrillation Devices
developed rapidly, with an average growth rate of 8.64%. In 2017, global revenue of Atrial Fibrillation Devices is nearly 2.4 billion USD. The atrial fibrillation surgery market has immense growth potential from 2018 to 2025. The factors propelling growth in this market include increasing number of people suffering from atrial fibrillation and favorable regulations.
About 4.4% people out of diagnosed atrial fibrillation population are treated using ablation technology in the U.S., Europe, and Japan combined. The atrial fibrillation population treated with ablation is expected to grow with a double digit rate in these regions. The increasing prevalence of atrial fibrillation and advancement in the ablation technologies drive the use of ablation products in the treatment of atrial fibrillation.
This market is segmented, on the basis of surgical procedures, into catheter ablation and surgical ablation. Catheter ablation procedures hold the maximum share in this market and are expected to grow with the highest CAGR during forecast period of 2018 to 2025.
The geographical segmentation includes North America, Europe, Asia-Pacific, South America and Middle East & Africa. North America holds the largest share in this market. However, Asia-Pacific is expected to witness the highest growth rate owing to the presence of a large patient population, growing medical tourism, and high focus of global market players on emerging Asia-Pacific countries such as China and India.